Aldeyra Therapeutics (ALDX) Operating Expenses (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported Operating Expenses for 14 consecutive years, with $5.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 42.47% year-over-year to $5.9 million; the trailing twelve-month figure through Jun 2026 stood at $24.1 million (down 54.86% YoY), and the FY2025 full-year result was $35.3 million, down 41.34% from the prior year.
• Operating Expenses improved to $5.9 million in Q2 2026 per ALDX's latest filing, from $3.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $18.0 million in Q2 2024 and bottomed at $3.5 million in Q1 2026.
• Historically, Operating Expenses has averaged $11.7 million across 5 years, with a median of $10.4 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Operating Expenses soared 171.87% in 2024, then sank 65.98% in 2026.
• Over 5 years, Operating Expenses stood at $13.7 million in 2022, then slumped by 55.48% to $6.1 million in 2023, then surged by 171.87% to $16.6 million in 2024, then tumbled by 59.78% to $6.7 million in 2025, then fell by 12.26% to $5.9 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $5.9 million, $3.5 million, and $6.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.